Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in China

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 8, 2008, Pages 2980-2983

  Fu, Yingmei ^a,b   Guo, Lishuang ^a   Xu, Yan ^a   Zhang, Wenli ^a   Gu, Jiaao ^a   Xu, Jianfeng ^a   Chen, Xiaobei ^a   Zhao, Yuehui ^a   Ma, Jiayu ^a   Liu, Xinghan ^b   Zhang, Fengmin ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ISOLEUCINE; NALIDIXIC ACID; QUINOLONE DERIVATIVE; SERINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHINA; DRUG SENSITIVITY; GENE MUTATION; KLEBSIELLA PNEUMONIAE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; QUINOLONES;

EID: 48749111332     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00151-08     Document Type: Article

References (25)

1. Brisse, S., D. Milatovic, A. C. Fluit, J. Verhoef, N. Martin, S. Scheuring, K. Köhrer, and F. L. Schmitz. 1999. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob. Agents Chemother. 43:2051-2055.
2. Brisse, S., and J. Verhoef. 2001. Phylogenetic diversity of Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates revealed by randomly amplified polymorphic DNA, gyrA and parC genes sequencing and automated ribotyping. Int. J. Syst. Evol. Microbiol. 51:915-924.
3. Reference deleted.
4. Deguchi, T., A. Fukuoka, M. Yasuda, M. Nakano, S. Ozeki, E. Kanematsu, Y. Nishino, S. Ishihara, Y. Ban, and Y. Kawada. 1997. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41:699-701.
5. Deguchi, T., M. Yasuda, T. Kawamura, M. Nakano, S. Ozeki, E. Kanematsu, Y. Nishino, and Y. Kawada. 1997. Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob. Agents Chemother. 11:2544-2546.
6. Deguchi, T., T. Kawamura, M. Yasuda, M. Nakano, H. Fukuda, H. Kato, N. Kato, Y. Okano, and Y. Kawada. 1997. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Antimicrob. Agents Chemother. 41:1609-1611.
7. SHV related to susceptibility to ampicillin in Klebsiella pneumoniae. Int. J. Antimicrob. Agents 29:344-347.
8. Gruteke, P., W. Goessens, J. Van Gils, P. Peerbooms, N. Lemmens-Den Toom, M. Van Santen-Verheuvel, A. Van Belkum, and H. Verbrugh. 2003. Patterns of resistance associated with integrons, the extended-spectrum β-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak. J. Clin. Microbiol. 41:1161-1166.
9. Kern, W. V., M. Oethinger, A. S. Jellen-Ritter, and S. B. Levy. 2000. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44:814-820.
10. Linde, H. J., F. Notka, C. Irtenkauf, J. Decker, J. Wild, H. H. Niller, P. Heisig, and N. Lehn. 2002. Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. J. Antimicrob. Chemother. 49:625-630.
11. Martínez-Martínez, L., A. Pascual, C. Conejo Mdel, I. García, P. Joyanes, A. Doménech-Sánchez, and V. J. Benedí. 2002. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum β-lactamase production. Antimicrob. Agents Chemother. 46:3926-3932.
12. Martínez-Martínez, L., A. Pascual, S. Hernandez-Alles, D. Alvarez-Diaz, A. I. Suarez, J. Tran, V. J. Benedi, and G. A. Jacoby. 1999. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43:1669-1673.
13. Martínez-Martínez, L., I. García, S. Ballesta, V. J. Benedí, S. Hernández-Allés, and A. Pascual. 1998. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 42:1850-1852.
14. Mery De la Fuente, C. M., S. P. Dauros, T. H. Bello, Y. M. Domínguez, M. S. Mella, A. M. Sepúlveda, Z. R. Zemelman, and R. G. González. 2007. Mutations in gyrA and gyrB genes among strains of gram-negative bacilli isolated from Chilean hospitals and their relation with resistance to fluoroquinolones. Rev. Med. Chil. 135:1103-1110.
15. NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. NCCLS, Wayne, PA.
16. Oethinger, M., I. Podglajen, W. V. Kern, and S. B. Levy. 1998. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob. Agents Chemother. 42:2089-2094.
17. Piddock, L. J. 1999. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58:11-18.
18. Rodríguez-Martínez, J. M., C. Velasco, I. García, M. E. Cano, L. Martínez-Martínez, and A. Pascual. 2007. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob. Agents Chemother. 51:2236-2239.
19. Sader, H. S., A. T. Ferreira, I. I. Tosin, A. C. Gales, L. S. Keim, J. M. Carbadillo, S. J. Melle, Jr., and W. Tavares. 1998. Piperacillin/ tazobactam: evaluation of its in vitro activity against bacteria isolated in two Brazilian hospitals and an overview of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Braz. J. Infect. Dis. 2:241-255.
20. Schneiders, T., S. G. Amyes, and S. B. Levy. 2003. Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob. Agents Chemother. 47:2831-2837.
21. Strahilevitz, J., D. Engelstein, A. Adler, V. Temper, A. E. Moses, C. Block, and A. Robicsek. 2007. Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 to 2005. Antimicrob. Agents Chemother. 51:3001-3003.
22. Reference deleted.
23. Reference deleted.
24. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.
25. Zhang, R., K. Eggleston, V. Rotimi, and R. J. Zeckhauser. 7 April 2006, posting date. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2:6. doi:10.1186/1744-8603-2-6.